Sanofi PE Ratio 2006-2018 | SNY

Current and historical price to earnings ratio for Sanofi (SNY) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Sanofi as of August 20, 2018 is 13.35.
Sanofi Annual PE Ratio
Sanofi Quarterly PE Ratio
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $105.440B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
Merck (MRK) United States $186.199B 16.44
AbbVie (ABBV) United States $149.625B 14.62
Novo Nordisk (NVO) Denmark $115.970B 18.54
Eli Lilly (LLY) United States $113.359B 20.98
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62